Benjamin P. Levy, MD, discusses the value in leveraging clinical trials to determine the potential of utilizing checkpoint inhibitors as single agent first line therapies and in combination with chemotherapy as a second line strategy.
Related Items
Conference Correspondent published on June 6, 2016 in ASCO 2016 - Lung Cancer
Conference Correspondent published on June 4, 2016 in ASCO 2016 - Lung Cancer
Conference Correspondent published on June 4, 2016 in ASCO 2016 - Lung Cancer
Last modified: June 4, 2016